Literature DB >> 26705758

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.

Remi A Kessler1, Maureen A Mealy1, Michael Levy2.   

Abstract

OPINION STATEMENT: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.

Entities:  

Keywords:  Azathioprine; Eculizumab; Immunosuppression; Mycophenolate; Neuromyelitis optica spectrum disorder; Rituximab

Year:  2016        PMID: 26705758      PMCID: PMC4807395          DOI: 10.1007/s11940-015-0387-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  65 in total

1.  Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.

Authors:  C Costanzi; M Matiello; C F Lucchinetti; B G Weinshenker; S J Pittock; J Mandrekar; P Thapa; A McKeon
Journal:  Neurology       Date:  2011-08-03       Impact factor: 9.910

2.  Rehabilitation results of patients with acute transverse myelitis.

Authors:  M Calis; M Kirnap; H Calis; S Mistik; H Demir
Journal:  Bratisl Lek Listy       Date:  2011       Impact factor: 1.278

Review 3.  Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.

Authors:  Jodie M Burton; Paul W O'Connor; Marika Hohol; Joseph Beyene
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

Authors:  Howard J Eisen; Jon Kobashigawa; Anne Keogh; Robert Bourge; Dale Renlund; Robert Mentzer; Edwin Alderman; Hannah Valantine; Georges Dureau; Donna Mancini; Richard Mamelok; Robert Gordon; Whedy Wang; Mandeep Mehra; Maria Rosa Constanzo; Manfred Hummel; Jay Johnson
Journal:  J Heart Lung Transplant       Date:  2005-05       Impact factor: 10.247

Review 5.  Regenerative cellular therapies for neurologic diseases.

Authors:  Michael Levy; Nicholas Boulis; Mahendra Rao; Clive N Svendsen
Journal:  Brain Res       Date:  2015-07-31       Impact factor: 3.252

Review 6.  An update on prevention and treatment of catheter-associated urinary tract infections.

Authors:  Peter Tenke; Béla Köves; Truls E B Johansen
Journal:  Curr Opin Infect Dis       Date:  2014-02       Impact factor: 4.915

7.  Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.

Authors:  So-Young Huh; Su-Hyun Kim; Jae-Won Hyun; Ae-Ran Joung; Min Su Park; Byung-Jo Kim; Ho Jin Kim
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

Review 8.  Urinary incontinence in women.

Authors:  Lauren N Wood; Jennifer T Anger
Journal:  BMJ       Date:  2014-09-15

9.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  30 in total

Review 1.  Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Authors:  Masanori Nakazawa; Hitoshi Ishikawa; Taiji Sakamoto
Journal:  Jpn J Ophthalmol       Date:  2021-05-22       Impact factor: 2.447

2.  Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.

Authors:  Jia Liu; Li Xu; Zhuo-Lin Chen; Min Li; Huan Yi; Fu-Hua Peng
Journal:  Bosn J Basic Med Sci       Date:  2018-02-20       Impact factor: 3.363

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 4.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 5.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

Review 6.  Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.

Authors:  Savino Sciascia; Massimo Radin; Jinoos Yazdany; Maria Tektonidou; Irene Cecchi; Dario Roccatello; Maria Dall'Era
Journal:  Rheumatol Int       Date:  2017-03-03       Impact factor: 2.631

7.  Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.

Authors:  Maureen A Mealy; Su-Hyun Kim; Felix Schmidt; Reydmar López; Jorge A Jimenez Arango; Friedemann Paul; Dean M Wingerchuk; Benjamin M Greenberg; Ho Jin Kim; Michael Levy
Journal:  Mult Scler       Date:  2017-08-31       Impact factor: 6.312

Review 8.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

9.  Images of the month: Intractable vomiting and neuromyelitis optica spectrum disorder.

Authors:  Seng Wee Cheo; Qin Jian Low; Yee Ann Tan; Yuen Kang Chia
Journal:  Clin Med (Lond)       Date:  2020-05       Impact factor: 2.659

10.  Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.

Authors:  Itay Lotan; Richard McGowan; Michael Levy
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.